CN Patent

CN116710100A — 用于治疗进行性家族性肝内胆汁淤积(pfic)的奥德昔巴特

Assigned to Albireo AB · Expires 2023-09-05 · 3y expired

What this patent protects

本文提供了用回肠胆汁酸转运(IBAT)抑制剂(例如奥德昔巴特或其药学上可接受的盐)治疗进行性家族性肝内胆汁淤积(PFIC)的方法。此类方法可包括降低平均瘙痒评分、平均血清胆汁酸浓度、增加身高、使体重正常化、改善睡眠和改善肝脏参数。

USPTO Abstract

本文提供了用回肠胆汁酸转运(IBAT)抑制剂(例如奥德昔巴特或其药学上可接受的盐)治疗进行性家族性肝内胆汁淤积(PFIC)的方法。此类方法可包括降低平均瘙痒评分、平均血清胆汁酸浓度、增加身高、使体重正常化、改善睡眠和改善肝脏参数。

Drugs covered by this patent

maralixibat-chloride (MARALIXIBAT CHLORIDE)

Patent Metadata

Patent number: CN116710100A
Jurisdiction: CN
Classification: —
Expires: 2023-09-05
Drug substance claim: No
Drug product claim: No
Assignee: Albireo AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.